PGBCY.US PGBCY
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is PGBCY.US undervalued?
Graham numberThe Graham number of PGBCY cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PGBCY fundamental analysis
No fundamental analysis for PGBCY yet.
PGBCY stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PGBCY
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid recep…
Full company profileFinancial statements of PGBCY are not available yet.
PGBCY dividends
PGBCY has not paid dividends in the last 1 fiscal years.
Who owns PGBCY
Ownership data of PGBCY is not available yet.
PGBCY company profile
- Company name
- PGBCY
- Ticker
- PGBCY.US
- Exchange
- USA Stocks
- Sector
- -
- Industry
- -
- Employees
- 53
- Fiscal year end
- December
- Address
- Room 606, Hangzhou, China
- Phone
- 86 512 6295 6128
- Website
- pegbio.com
About PGBCY
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. It has research and development collaboration with rani therapeutics to expand obesity pipeline across multiple novel candidates. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
PGBCY management
7- Dr. Min XuExecutive Chairman of the Board & GM · born 1965
- Ms. Xiaojun WangCFO & Executive Director · born 1969
- Ms. Chuanzhen LiuHead of Regulatory Affairs
- Jianhui WangHead of Macromolecular Drug Discovery
- Dr. Nengyin LiuHead of Drug Discovery
- Mr. Yifeng HUANGJoint Company Secretary & Board Secretary · born 1989
- Ms. Yan Ting KwokJoint Company Secretary